search
Back to results

On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication

Primary Purpose

Chronic Use of Acid Suppressive Medication, GORD, GERD

Status
Unknown status
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
pantoprazole 20 mg (drug)
Sponsored by
UMC Utrecht
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Use of Acid Suppressive Medication focused on measuring on-demand therapy, pantoprazole, gastro-oesophageal reflux disease, proton pump inhibitor, acid suppression, intermittent

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: male and female (non-pregnant, non-lactating)out-patients between 18-75 chronic users of acid suppressive therapy for at least 180 days over the last year Exclusion Criteria: stage 3, 4 oesophagitis, Barrett's oesophagus, acute peptic ulcer gastric hypersecretory condition, predominantly IBS symptoms, previous gastric/oesophageal surgery, pyloric stenosis severe, unstable comorbidities alarm symptoms malignancies in the past 5 years use of NSAID, systemic glucocorticoids, Cox-2 inhibitors, acetylsalicylic acid more than 150 mg daily, drugs with pH-dependent absorption, anticholinergics

Sites / Locations

    Outcomes

    Primary Outcome Measures

    The percentage of patients taking 6 or more tablets on-demand per week (averaged from week 5-17.

    Secondary Outcome Measures

    -mean weakly consumption of on-demand tablets
    -percentage of patients in placebo group requiring less than 2 tablets pantoprazole per week
    -proportion of patients with adequate relief per treatment group per week
    -quality of life during double-blind phase (via SF-36 and QOLRAD for GERD symptom score)
    -predictors of the primary outcome (age, sex, general medical and gastrointestinal history, Hp status, BMI, lifestyle factors, personality and psychological state)
    -proportion of patients successfully changed from omeprazole to pantoprazole, or from 40 mg to 20 mg
    -costs during all phases
    -cost-effectiveness

    Full Information

    First Posted
    September 8, 2005
    Last Updated
    February 1, 2006
    Sponsor
    UMC Utrecht
    Collaborators
    Takeda
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00161096
    Brief Title
    On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
    Official Title
    Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2004
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    September 2005 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    UMC Utrecht
    Collaborators
    Takeda

    4. Oversight

    5. Study Description

    Brief Summary
    The purpose of this study is to investigate several aspects of chronic use of acid suppressing medication: dependence on maintenance therapy, the possibilities for on-demand use, and predictors (patient characteristics) for daily need, for on-demand use and for termination of chronic use.
    Detailed Description
    2-5% of the general population is chronic user of acid suppressing medication (proton pump inhibitors, H2 receptor antagonists), mostly because of gastro-oesophageal reflux disease (GORD). Prescription data from health insurances show that the number of chronic users increases every year, which has large economic consequences. There are indications however that on-demand and intermittent therapy can be as effective as daily use. No evidence exists regarding patients who are likely to benefit from intermittent, on-demand therapy or even termination. In this study several aspects of chronic use of acid suppressive therapy are investigated in family practice patients. Chronic users are transferred to pantoprazole 20 mg for 4 weeks. Patients with adequate relief of symptoms are randomized in two groups for a period of 13 weeks. group 1: daily pantoprazole 20 mg, placebo on-demand (indicative for placebo-dependency) group 2: daily placebo, pantoprazole 20 mg on-demand (indicative for pharmacological dependency) Patients visit the research nurse at the beginning of the study and at week 4, 5, 10 and 17. In this study we are looking for patient characteristics indicative for the dependency on acid suppressive drugs and for possibilities to reduce the dose of these drugs. Furthermore, aspects described in "secondary outcomes" will be addressed.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Use of Acid Suppressive Medication, GORD, GERD, Reflux, Peptic Ulcer
    Keywords
    on-demand therapy, pantoprazole, gastro-oesophageal reflux disease, proton pump inhibitor, acid suppression, intermittent

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    276 (false)

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    pantoprazole 20 mg (drug)
    Primary Outcome Measure Information:
    Title
    The percentage of patients taking 6 or more tablets on-demand per week (averaged from week 5-17.
    Secondary Outcome Measure Information:
    Title
    -mean weakly consumption of on-demand tablets
    Title
    -percentage of patients in placebo group requiring less than 2 tablets pantoprazole per week
    Title
    -proportion of patients with adequate relief per treatment group per week
    Title
    -quality of life during double-blind phase (via SF-36 and QOLRAD for GERD symptom score)
    Title
    -predictors of the primary outcome (age, sex, general medical and gastrointestinal history, Hp status, BMI, lifestyle factors, personality and psychological state)
    Title
    -proportion of patients successfully changed from omeprazole to pantoprazole, or from 40 mg to 20 mg
    Title
    -costs during all phases
    Title
    -cost-effectiveness

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: male and female (non-pregnant, non-lactating)out-patients between 18-75 chronic users of acid suppressive therapy for at least 180 days over the last year Exclusion Criteria: stage 3, 4 oesophagitis, Barrett's oesophagus, acute peptic ulcer gastric hypersecretory condition, predominantly IBS symptoms, previous gastric/oesophageal surgery, pyloric stenosis severe, unstable comorbidities alarm symptoms malignancies in the past 5 years use of NSAID, systemic glucocorticoids, Cox-2 inhibitors, acetylsalicylic acid more than 150 mg daily, drugs with pH-dependent absorption, anticholinergics
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Mattijs E Numans, MD, PhD
    Organizational Affiliation
    Julius Center for Health Sciences and Primary Care
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication

    We'll reach out to this number within 24 hrs